Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Porto
Clinical trial register · Portugal

Clinical Trials in Porto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1100 matching records held by the registry are in this view. Synced 03 Oct 2026, 03:16 UTC
1100
Studies in scope
all four open statuses
535
Recruiting now
open to new participants
284
Lead sponsors
across recruiting studies
Top sites
Lisbon 683 Porto 541 Coimbra 258 Braga 180 Vila Nova de Gaia 108
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universidade do Porto33 Janssen Research & Development, LLC30 AbbVie26 AstraZeneca26 Hoffmann-La Roche24
Site location
Lisbon683 Porto541 Coimbra258 Braga180 Vila Nova de Gaia108
All 96 locations
Target enrolment
to

Trials with a site in Porto

541 of 1100 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Not yet open
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
NCT07829198Obesity
DrugTirzepatide
Universidade do Porto
Phase 3
70
Porto, Santa Maria da Feira
2027-01
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Vila Nova de Gaia, Lisbon, Loures, Porto
2026-12-16
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Lisbon, Vila Nova de Gaia, Braga, Porto
2026-11-30
Not yet open
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies
NCT07839819Advanced Solid Tumor
DrugsPM54·Doxorubicin·Irinotecan
PharmaMar
Phase 1/2
231
Lisbon, Porto
2026-11-12
Not yet open
The Effect of a Treatment Protocol Focused on Neuromuscular Control Exercises on Pain and Function in a Subgroup of Individuals With Patellofemoral Pain
NCT06893289Patellofemoral Pain
Universidade do Porto
Not applicable
24
Porto
2026-10-01
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
DrugsVVD-133214·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 2
140
Coimbra, Lisbon, Porto
2026-09-11
Not yet open
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 3
150
Lisbon, Porto
2026-09
Not yet open
Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study
NCT07772544Psoriatic Arthritis (PsA)
Sociedade Portuguesa de Reumatologia
Not applicable
72
Aveiro, Lisbon, Porto
2026-09
Not yet open
TIVA Mobile Health Intervention for Family Caregivers
NCT07616284Positive Mental Health, Family Caregivers, Mental Health Promotion, Caregiver Burden
Universidade do Porto
Not applicable
80
Porto
2026-09
Not yet open
Influence of Osteopathic Intervention on Cervical Muscles in Tension Headaches in Women
NCT06475248Tension Headaches
Escola Superior de Tecnologia da Saúde do Porto
Not applicable
43
Porto
2026-09
Recruiting
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
NCT07630714Systemic Lupus Erythematosus
AstraZeneca
Phase 2
24
Lisbon, Porto
2026-08-31
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Braga, Lisbon, Porto
2026-08-31
Not yet open
MyGENESIS-PATH: Digital Program for Donor-Conceived People
NCT07457697Psychosocial Stress
Universidade do Porto
Not applicable
60
Porto
2026-08-18
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Almada, Coimbra, Lisbon, Ponte de Lima, Porto
2026-07-27
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Lisbon, Porto
2026-07-10
Recruiting
E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors
NCT07754929Prostate Cancer
Universidade do Porto
Not applicable
106
Porto
2026-07-01
Not yet open
Immediate Restoration of a New Implant With High Primary Stability
NCT07498556Dental Implants, Immediate Dental Implant Loading
Universidade do Porto
Not applicable
50
Porto
2026-07-01
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Coimbra, Lisbon, Porto, Torres Vedras
2026-07-01
Not yet open
Psoas Major Muscle Intervention on Chronic Lumbar Pain in Cleaning Professionals.
NCT07672197Lumbar Pain, Non-specific Low Back Pain (NSLBP)
Escola Superior de Tecnologia da Saúde do Porto
Not applicable
30
Porto
2026-07
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634Multiple Myeloma
DrugsRamantamig·Tocilizumab
Janssen Research & Development, LLC
Phase 2
230
Braga, Lisbon, Porto
2026-06-30
Recruiting
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
NCT07507760Acute Myeloid Leukemia With Gene Mutations
DrugsDecitabine/Cedazuridine·Hydroxyurea·Ivosidenib·Cytarabine
PETHEMA Foundation
Phase 2
50
Aveiro, Funchal, Lisbon, Porto
2026-06-12
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Coimbra, Lisbon, Porto
2026-06-01
Not yet open
EMBRACE - From Vulnerable to Empowered: Implementation and Evaluation of a Multicomponent Program to Tackling Age-related Decline
NCT07628686Age-Related Cognitive Decline
University Fernando Pessoa
Not applicable
120
Porto
2026-06-01
Not yet open
Effects of an Osteopathic Manual Therapy Protocol on Heart Rate Variability, Stress, and Anxiety in Young Adults
NCT07670806Stress, Anxiety
Escola Superior de Tecnologia da Saúde do Porto
Not applicable
30
Porto
2026-06
Not yet open
Effect of Osteopathic Technique on Maximum Mouth Opening Width, Masseter Muscle Tone and Stiffness
NCT07670832Asymptomatic Condition
Escola Superior de Tecnologia da Saúde do Porto
Not applicable
32
Porto
2026-06
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 3
990
Guimarães, Loures, Almada, Lisbon, Porto
2026-05-22
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine
Hoffmann-La Roche
Phase 2/3
650
Amadora-Lisbon, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia
2026-05-21
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Alcabideche, Almada, Braga, Lisbon, Porto, Senhora Da Hora, Matosinhos, Vila Nova de Gaia
2026-05-20
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 3
350
Lisbon, Porto, Coimbra
2026-05-14
Recruiting
Effectiveness of a Positive Mental Health Promotion Programme for Informal Caregivers of People With Dementia
NCT07577440Mental Health
University Rovira i Virgili
Not applicable
108
Porto
2026-05-03
Recruiting
Augmented Reality-Based Binocular Therapy for Visual Rehabilitation in Adults With Amblyopia
NCT07819552Amblyopia, Anisometropic Amblyopia
Polytechnic Institute of Porto
Not applicable
60
Coimbra, Porto
2026-05-01
Not yet open
Home Monitoring in eAMD Treatment
NCT07340372Exudative Age-Related Macular Degeneration
DrugAflibercept
Association for Innovation and Biomedical Research on Light and Image
Observational
80
Coimbra, Leiria, Lisbon, Loures, Porto
2026-05
Not yet open
Study of Hyaluronic Acid Used With Gum Surgery to Treat Gum Recession in Adults
NCT07529340Gingival Recession, Mucogingival Surgery
Universidade do Porto
Not applicable
34
Porto
2026-05
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Almada, Porto
2026-04-23
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Pulmonary Arterial Hypertension
Inhibikase Therapeutics
Phase 3
486
Porto
2026-04-23
By invitation
Porcine Derma for Soft Tissue Augmentation Around Implants
NCT07436091Soft Tissue Augmentation Around Dental Implants
Universidade do Porto
Not applicable
15
Porto
2026-04-01
Recruiting
InRAD Observational Study
NCT07213700Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
Observational
50,000
Porto
2026-03-30
Recruiting
Mobile App vs. In-Person Pelvic Floor Rehabilitation for Urinary Leakage in Adult Women
NCT07597174Urinary Incontinence , Stress
Unidade Local de Saúde São João, Oporto
Not applicable
32
Porto
2026-03-26
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 3
770
Lisbon, Porto
2026-03-24
Recruiting
PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care
NCT07711821Heart Failure
Universidade do Porto
Not applicable
160
Amadora, Lisbon, Porto
2026-03-23
Recruiting
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT07387367Adenovirus Infections
SymBio Pharmaceuticals
Phase 3
180
Lisbon, Porto
2026-03-17
Recruiting
ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder
NCT07474974Depression - Major Depressive Disorder, Treatment Resistant Depression
Polytechnic Institute of Porto
Not applicable
44
Porto
2026-03-15
Active, closed
Expert Validation of an Autonomous Personalized Physical Activity Algorithm
NCT07475221Experts in Physical Activity Prescription and Risk Health Screening
Polytechnic Institute of Porto
Observational
9
Porto
2026-03-10
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
Almada, Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia
2026-03-05
Active, closed
Evaluating the Mentalization-based Treatment Lighthouse Parenting Programme: Protocol of a Feasibility and Acceptability Quasi-Experimental Study
NCT07448870Being Referred for Child Protection Services
Universidade do Porto
Not applicable
60
Porto
2026-03-01
Recruiting
To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.
NCT07493421Pancreatic Adenocarcinoma, Peritoneal (Metastatic) Cancer
Unidade Local de Saúde São João, Oporto
Not applicable
20
Lisbon, Porto
2026-03-01
Not yet open
Suprascapular Nerve Block to Improve Tolerance and Outcomes of Shoulder Hydrodistension in Adhesive Capsulitis
NCT07380087Adhesive Capsulitis, Adhesive Capsulitis of Unspecified Shoulder, Adhesive Capsulitis, Shoulder, Frozen Shoulder
Universidade do Porto
Not applicable
50
Porto
2026-03-01
Recruiting
Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Homes (MOVE4CARE)
NCT07392944Frailty, Dementia
Universidade do Porto
Not applicable
60
Porto
2026-02-18
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Almada, Amadora, Braga, Coimbra, Lisbon, Loures, Porto, Setúbal
2026-02-16
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dovato·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
Porto, Vila Nova de Gaia
2026-02-11
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Braga, Porto, Viana do Castelo, Vila Nova de Gaia
2026-02-05
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
DrugsNucresiran·Vutrisiran
Alnylam Pharmaceuticals
Phase 3
125
Lisbon, Porto
2026-02-03
Not yet open
Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use
NCT07366892Suspected Grade III and IV Gliomas Requiring Surgical Intervention, Neurosurgical Procedure, Glioma, Glioblastoma (GBM)
Leica Microsystems (Schweiz) AG
Observational
37
Porto
2026-02-01
Not yet open
Evaluating the Impact of In-Situ Simulation on Interprofessional Healthcare Team Training
NCT07346937in Situ Simulation, Simulation in Training Center
Universidade do Porto
Not applicable
108
Matosinhos Municipality, Porto
2026-02
Recruiting
Leica Microsystems Sponsored Study to Collect and Confirm Clinical Data on the Performance of the GLOW800 Device When Used in Accordance With Its Intended Use.
NCT07164040Reconstructive Surgical Procedures, Plastic Surgery, Vascular Surgical Procedure, Cerebrovascular Disorder
Leica Microsystems (Schweiz) AG
Observational
29
Porto
2026-01-20
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
Lisbon, Porto
2026-01-16
Recruiting
PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI
NCT07343674Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II)
Portuguese Association of Interventional Cardiology
Observational
500
Coimbra, Lisbon, Funchal, Porto, Vila Nova de Gaia, Evora
2026-01-14
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Braga, Matosinhos Municipality, Porto, Viana do Castelo, Vila Nova de Gaia
2026-01-12
Recruiting
Assessing Agreement Between Acuvera Capture and Paper-Based Methods for BCVA Data Recording in Ophthalmic Trials
NCT07613580Ophthalmopathy
OptymEdge, LLC
Observational
90
Coimbra, Porto
2026-01-12
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
460
Porto, Vila Nova de Gaia
2026-01-08
Recruiting
Care4mommies in Action: A Compassion-based Intervention
NCT07611175Pregnancy Related
Portucalense University
Not applicable
96
Porto
2026-01-02
Not yet open
Effects of an Elastic Band Warm-Up on Sprint and Vertical Jump Performance in Female Football Players
NCT07316881Physical Performance Parameters
University Institute of Maia
Not applicable
22
Porto
2026-01
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Guimarães, Loures, Senhora da Hora, Braga, Porto
2025-12-10
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Coimbra, Lisbon, Porto
2025-12-09
Not yet open
Acute Cardiovascular and Neuromuscular Responses to Walking With Blood Flow Restriction (BFR) in Older Adults
NCT07275138Healthy Older Adults
Universidade da Coruña
Not applicable
20
Porto
2025-12-08
Recruiting
Virtual Reality for Recovery After Intensive Care (PICS)
NCT07585500Post-Intensive Care Syndrome (PICS), Critical Illness Recovery, Rehabilitation After Critical Illness, Rehabilitation Exercise of ICU Patients
University of Minho
Not applicable
51
Porto
2025-12-06
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Lisbon, Portimão, Porto, Vila Nova de Gaia
2025-12-03
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
Figueira da Foz Municipality, Porto
2025-12-03
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Lisbon, Porto, Vila Nova de Gaia
2025-11-28
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
DrugsBevacizumab·Carboplatin
AbbVie
Phase 1
285
Lisbon, Porto
2025-11-27
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Carnaxide, Coimbra, Lisbon, Porto
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Torres Novas, Lisbon, Porto, Vila Nova de Gaia
2025-11-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
250
Coimbra, Lisbon, Porto
2025-11-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Braga, Lisbon, Porto
2025-11-11
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Coimbra, Porto
2025-11-10
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin
Boehringer Ingelheim
Phase 3
670
Braga, Coimbra, Lisbon, Porto
2025-11-07
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Coimbra, Lisbon, Porto
2025-11-05
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Coimbra, Lisbon, Porto
2025-11-03
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Coimbra, Gaia, Porto
2025-10-28
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Coimbra, Lisbon, Porto
2025-10-27
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Lisbon, Porto
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Braga, Loures, Porto, Vila Nova de Gaia
2025-10-24
Recruiting
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
NCT07220564Haemophilia A
Novo Nordisk A/S
Phase 1
30
Porto
2025-10-23
Active, closed
Mixed Reality vs. Traditional Arthroscopic Simulation
NCT07648056Surgical Education, Clinical Competence
Universidade da Coruña
Not applicable
25
Porto
2025-10-20
Active, closed
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 2
60
Lisbon, Porto
2025-10-13
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 2/3
1,092
Braga, Guimarães, Lisbon, Loures, Porto
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
882
Braga, Guimarães, Lisbon, Loures, Porto, Viana do Castelo
2025-10-01
Recruiting
BioNortHealth Project
NCT07833787College Students
Polytechnic Institute of Porto
Observational
1,500
Porto
2025-10-01
Recruiting
Psychodrama Group Therapy for Breakup Distress and Relationship Adjustment: A Randomized Trial
NCT07658248Breakup Distress, Dyadic Adjustment
Universidade do Porto
Not applicable
42
Porto
2025-09-23
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
DrugLunsekimig
Sanofi
Phase 3
942
Almada, Guimarães, Matosinhos Municipality, Porto
2025-09-16
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Lisbon, Coimbra, Porto
2025-09-11
Not yet open
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
NCT06200779Helicobacter Pylori Infection
Manuel Coelho da Rocha
Phase 4
160
Porto
2025-09
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Porto
2025-08-22
Recruiting
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
NCT06709339Polypoidal Choroidal Vasculopathy
DrugsVabysmo·Faricimab
Association for Innovation and Biomedical Research on Light and Image
Phase 4
120
Coimbra, Leiria, Lisbon, Loures, Porto
2025-08-06
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Non-Squamous Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
854
Braga, Porto
2025-08-03
Active, closed
Effects of 20-week Mat-Pilates & Dual-Task Training on Strength, Balance, Cognition, and Fall Risk in Older Adults
NCT07119762Healthy People Programs
Universidade do Porto
Not applicable
67
Porto
2025-08-01
Active, closed
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
NCT06878365Type 1 Interferonopathies
Boehringer Ingelheim
Phase 1
16
Lisbon, Porto
2025-07-29
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
Coimbra, Lisbon, Porto
2025-07-24
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Lisbon, Braga, Porto
2025-07-23
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Torres Vedras, Matosinhos Municipality, Braga, Coimbra, Guimarães, Porto
2025-07-21
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Alcabideche, Lisbon, Porto
2025-07-17
Active, closed
DanceOn50+: Effects of a Dance Program on Physical and Psycho-emotional Health
NCT07158866Physical Activity, Physical Fitness, Well Being
Universidade do Porto
Not applicable
110
Porto
2025-07-15
Active, closed
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
NCT06892288Phosphomannomutase 2 Deficiency, PMM2-CDG
Glycomine, Inc.
Phase 2/3
50
Porto
2025-07-09
Recruiting
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
NCT07067437Breast Neoplasms
National Institute of Oncology, Hungary
Not applicable
250
Porto
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Lisbon, Porto
2025-06-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725Niemann-Pick Type C Disease
DrugNizubaglustat
Azafaros B.V.
Phase 3
72
Porto
2025-06-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
DrugNizubaglustat
Azafaros B.V.
Phase 3
147
Porto, Lisbon
2025-06-30
Active, closed
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07082543Gangliosidoses, GM2, Gangliosidosis, GM1
DrugNizubaglustat
Azafaros B.V.
Phase 3
75
Porto, Lisbon
2025-06-30
Active, closed
Preliminary Efficacy of AdoptMindful2Care: A Mindful Parenting Post-adoption Intervention for Adoptive Parents
NCT07043660Parenting Stress
University of Coimbra
Not applicable
78
Aveiro, Coimbra, Lisbon, Porto
2025-06-30
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
DrugsCDK4/6i·Trastuzumab deruxtecan
MedSIR
Phase 2
200
Lordelo, Alcabideche, Amadora, Aveiro, Braga, Lisbon, Loures, Porto
2025-06-30
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Lisbon, Porto
2025-06-27
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Almada, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2025-06-25
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Aveiro, Braga, Coimbra, Guimarães, Leiria, Lisbon, Porto
2025-06-09
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Lisbon, Porto
2025-06-04
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Lisbon, Porto
2025-06-04
Recruiting
Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke
NCT07232498Arterial Ischemic Stroke
Unidade Local de Saúde de Coimbra, EPE
Not applicable
1,300
Coimbra, Lisbon, Porto
2025-06-04
Recruiting
Overweight and Obesity in Adolescents - Sleep Behavioral Intervention
NCT07255274Obesity and Overweight, Sleep Disorder
University of Beira Interior
Not applicable
126
Covilha, Porto
2025-06-03
Recruiting
LDL Cholesterol Reduction Following Ezetimibe Initiation
NCT07839741Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk, LDL Cholesterol
DrugEzetimibe
Universidade do Porto
Phase 4
100
Porto
2025-06-01
Recruiting
Mediterranean Diet Intervention for Maternal Postpartum
NCT07038681Postpartum, Cardiometabolic Factors, Cardiac Reverse Remodeling
Universidade do Porto
Not applicable
52
Porto
2025-05-31
Recruiting
Study on Safety and Performance of AdvanCore Bone Void Filler
NCT06736457Bone Fractures, Bone Defects, Bone Loss, Bone Graft
Artur Salgado SA
Not applicable
190
Guimarães, Porto, Tomar, Lordelo
2025-05-29
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Lisbon, Porto
2025-05-29
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Almada, Braga, Guimarães, Lisbon, Porto
2025-05-22
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Lisbon, Porto
2025-05-19
By invitation
A Multicenter Study to Optimize Microembolic Signal Classification Based on Double--Blind Multiparametric Assessment by Human Experts Using an Universal Graphical Interface [MESOMEGA]
NCT07172165Microemboli, Stroke, Transcranial Doppler Ultrasound
Universidade do Porto
Observational
850
Porto
2025-05-15
Recruiting
Portuguese Registry With Meril Myval THV Series - MyPORTuVal Registry
NCT06818435Aortic Valve Stenosis, TAVI(Transcatheter Aortic Valve Implantation)
Portuguese Association of Interventional Cardiology
Observational
150
Carnaxide, Coimbra, Evora, Lisbon, Porto
2025-05-13
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Braga, Lisbon, Porto, Santa Maria da Feira, Viseu
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Lisbon, Porto
2025-05-12
By invitation
ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients
NCT07070284Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation
Joan Sabater-Riera
Observational
500
Porto
2025-05-01
Recruiting
Combining Noninvasive Brain Stimulation and Augmented Reality-based Dichoptic Therapy for Treating Amblyopic Adults
NCT07752433Amblyopia, Anisometropic Amblyopia
Polytechnic Institute of Porto
Not applicable
80
Coimbra, Porto
2025-05-01
Not yet open
Determinants of the Nutritional Composition of Donor Human Milk
NCT06904924Human Milk Nutrition
Universidade do Porto
Observational
80
Porto
2025-05
Not yet open
Clinical Impact of a Digital Home-based Falls Prevention Program on Elderly People
NCT03750500Fall
Sword Health, SA
Not applicable
100
Porto
2025-05
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin
Mirati Therapeutics Inc.
Phase 3
630
Lisbon, Coimbra, Porto
2025-04-24
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Guimarães, Leiria, Lisbon, Porto
2025-04-15
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Alcabideche, Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto
2025-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
770
Lisbon, Porto
2025-04-09
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
Braga, Coimbra, Lisbon, Porto
2025-04-08
Recruiting
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
NCT05766839Hyperkalemia
DrugPatiromer
Vifor Pharma, Inc.
Phase 2
36
Porto
2025-04-06
Active, closed
Fiability of a Telerehabilitation Programme Based on the Neurodevelopmental Treatment (NDT) Model on Gross Motor Function and Functional Performance in Children With Cerebral Palsy.
NCT07394985Cerebral Palsy Children
Escola Superior Saúde Fernando Pessoa
Not applicable
20
Porto
2025-04-04
Recruiting
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
NCT07348302Rhinitis, Rhinoconjunctivitis
Inmunotek S.L.
Phase 3
736
Porto, Santarém
2025-04-02
Recruiting
Intervention Project to Increase Adherence to Colorectal Cancer Screening in Barcelos/Esposende
NCT06972160Colon and Rectal Cancer
Local Health Unit Barcelos/Esposende, Public Health Unit
Not applicable
1,038
Porto
2025-04-01
Not yet open
Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care
NCT06848270Palliative Care, Acute Myeloid Leukaemia
Universidade do Porto
Not applicable
50
Porto
2025-04-01
Not yet open
Investigation of the Mechanisms of the Gut-brain Axis in Binge Eating and Obesity.
NCT06823557Binge Eating Disorder, Obesity
Universidade do Porto
Phase 1
104
Porto
2025-04
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Coimbra, Lisbon, Porto
2025-03-27
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Almada, Lisbon, Loures, Porto
2025-03-21
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Braga, Lisbon, Porto, Santa Maria da Feira, Viseu
2025-03-17
Recruiting
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
NCT06571149Ischemic Stroke
DrugsAlteplase·Tenecteplase
Insel Gruppe AG, University Hospital Bern
Phase 4
906
Amadora, Coimbra, Funchal, Lisbon, Matosinhos Municipality, Porto
2025-03-14
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Porto
2025-03-12
Recruiting
Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome
NCT07173062Stroke, Coronary Arterial Disease (CAD), Myocardial Infarction (MI), Diabetes Mellitus
Universidade do Porto
Not applicable
150
Porto
2025-03-11
Recruiting
BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe
NCT06856902Cardiovascular Diseases, Endocrinology, Inmunology, Neurology
Technical University of Madrid
Not applicable
3,100
Lisbon, Porto
2025-03-01
By invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
NCT06823115Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
Indiana University
Observational
4,000
Lisbon, Porto
2025-03-01
Not yet open
Prehabilitation for Lung Cancer Patients Undergoing Lung Resection
NCT06802627Lung Cancer, Lung Resection
Universidade do Porto
Not applicable
200
Porto
2025-03-01
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Braga, Lisbon, Porto, Coimbra, Faro
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Braga, Guimarães, Lisbon, Porto
2025-02-27
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505Chronic Migraine
DrugAtogepant
AbbVie
Phase 3
420
Lisbon, Almada, Coimbra, Porto
2025-02-13
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
Guimarães, Matosinhos Municipality, Porto, Santa Maria da Feira
2025-02-12
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
324
Coimbra, Lisbon, Porto
2025-02-12
Active, closed
Evaluating the Efficacy of a New Sexual Violence Prevention Program With College Students
NCT06887361Sexual Violence
Universidade do Porto
Not applicable
200
Porto
2025-02-10
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
400
Senhora Da Hora, Matosinhos, Lisbon, Porto, Vila Nova de Gaia
2025-02-10
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
DrugAtogepant
AbbVie
Phase 3
468
Guimarães, Lisbon, Loures, Senhora da Hora, Almada, Aveiro, Braga, Porto
2025-02-10
Active, closed
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
875
Coimbra, Lisbon, Porto
2025-02-05
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Coimbra, Lisbon, Porto
2025-02-05
Recruiting
Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
NCT06487273Non-cystic Fibrosis Bronchiectasis
Physio-Assist
Not applicable
622
Braga, Creixomil, Porto
2025-02-03
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Almada, Braga, Coimbra, Lisbon, Porto
2025-01-31
Not yet open
Early Warning System for Allergic Rhinitis in the MASK-air® App
NCT06768736Allergic Rhinitis
Universidade do Porto
Not applicable
210
Porto
2025-01-30
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Braga, Coimbra, Lisbon, Portimão, Porto, Senhora da Hora, Vila Nova de Gaia
2025-01-28
Recruiting
Nutrition-based Interventions to Prevent Cognitive Decline
NCT06853405Cognitive Dysfunction, Cognition Disorder, Memory Disorders, Cognitive Impairment
Instituto de Saude Publica da Universidade do Porto
Not applicable
120
Porto
2025-01-27
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience
Merck Sharp & Dohme LLC
Phase 3
1,046
Braga, Lisbon, Porto
2025-01-27
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
70
Coimbra, Lisbon, Porto
2025-01-22
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Guimarães, Lisbon, Porto
2025-01-08
Not yet open
Optimal Articular Solutions With Intraosseous and Synovial Platelet-Rich Plasma
NCT06520059Knee Osteoarthritis
Universidade do Porto
Phase 4
50
Porto
2025-01-01
Active, closed
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369Non Squamous Non Small Cell Lung Cancer
DrugsEU-sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin
mAbxience Research S.L.
Phase 3
726
Lisbon, Matosinhos Municipality, Porto
2024-12-30
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
Braga, Lisbon, Porto
2024-12-26
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Frexalimab·Rilzabrutinib
Sanofi
Phase 2
84
Lisbon, Porto
2024-12-19
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Porto
2024-12-18
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2024-12-16
Active, closed
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu
2024-12-11
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019Familial Hypercholesterolemia - Heterozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
60
Coimbra, Lisbon, Porto
2024-12-09
Recruiting
Improving Learning and Memory in Portuguese Patients With Multiple Sclerosis
NCT06723444Multiple Sclerosis
Centro Hospitalar De São João, E.P.E.
Not applicable
80
Porto
2024-12-05
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2024-12-03
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Creixomil, Lisbon, Porto, Viseu
2024-12-03
Active, closed
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805HIV Infections
DrugsRpv La·Cabotegravir·B/F/TAF
ViiV Healthcare
Phase 3
326
Porto
2024-12-02
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Guimarães, Lisbon, Loures, Sintra, Torres Vedras, Coimbra, Porto
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Coimbra, Matosinhos Municipality, Porto, Setúbal
2024-11-25
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Lisbon, Porto
2024-11-19
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Lisbon, Porto
2024-11-19
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
125
Lisbon, Porto
2024-11-18
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
367
Coimbra, Lisbon, Porto
2024-11-11
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Braga, Porto
2024-10-29
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Lisbon, Coimbra, Porto
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Braga, Lisbon, Loures, Porto
2024-10-04
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Porto
2024-09-30
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
Loures, Vila Franca de Xira, Porto, Vila Nova de Gaia, Coimbra, Faro, Lisbon, Setúbal
2024-09-27
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
96
Coimbra, Lisbon, Porto
2024-09-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
DrugsPetosemtamab·Pembrolizumab
Merus B.V.
Phase 3
699
Coimbra, Lisbon, Portimão, Porto, Vila Real
2024-09-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Braga, Faro, Lisbon, Porto
2024-09-24
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Braga, Coimbra, Lisbon, Porto
2024-09-23
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Coimbra, Porto
2024-09-19
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Lisbon, Porto
2024-09-18
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu
2024-09-17
Active, closed
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Tectonic Therapeutic
Phase 2
191
Almada, Lisbon, Porto
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Lisbon, Porto
2024-09-03
Recruiting
Distinct Exercise Modalities on Gut Microbiome
NCT06545123Sarcopenia, Older Adults
Faculty of Sports- Research Center in Physical Activity, Health and Leisure
Not applicable
69
Porto
2024-09-01
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Matosinhos Municipality, Coimbra, Lisbon, Porto
2024-08-28
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 2
194
Lisbon, Porto
2024-08-27
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
675
Coimbra, Porto
2024-08-19
Active, closed
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Capecitabine
Novartis Pharmaceuticals
Phase 1/2
20
Porto
2024-08-14
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin
Genmab
Phase 3
379
Lisbon, Porto
2024-08-13
Active, closed
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045Diabetic Macular Edema (DME)
DrugsRestoret·Lucentis·Ranibizumab
EyeBiotech Ltd.
Phase 2/3
984
Coimbra, Porto
2024-08-07
Recruiting
"Breathlessness Diagnostics in a Box" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design
NCT07320703Breathlessness, Cardiovascular, Pulmonary, Mental Disease
General Practitioners Research Institute
Not applicable
900
Porto
2024-08-05
Recruiting
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
NCT06515821Colorectal Cancer
Firalis SA
Observational
4,100
Porto
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsSaruparib·Camizestrant·Exemestane·Anastrozole
AstraZeneca
Phase 3
788
Coimbra, Lisbon, Matosinhos Municipality, Porto, Vila Real
2024-08-01
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Lisbon, Porto, Vila Nova de Gaia
2024-07-31
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306Depressive Disorder, Major
DrugSeltorexant
Janssen Research & Development, LLC
Phase 3
752
Braga, Leiria, Lisbon, Loures, Ponta Delgada, Porto, Touguinho
2024-07-25
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
Almada, Coimbra, Lisbon, Porto
2024-07-19
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
963
Aveiro, Braga, Coimbra, Lisbon, Matosinhos Municipality, Porto, Setúbal, Vila Nova de Gaia
2024-07-11
Not yet open
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
NCT06371807Early Breast Cancer, Triple Negative Breast Cancer
DrugsCyclophosphamide·Paclitaxel·Carboplatin·Pembrolizumab
Fundacao Champalimaud
Phase 2
20
Lisbon, Porto
2024-07
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Braga, Lisbon, Porto
2024-06-29
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Guimarães, Lisbon, Porto
2024-06-27
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
DrugPetosemtamab
Merus B.V.
Phase 3
621
Coimbra, Lisbon, Porto
2024-06-25
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine
Merck Sharp & Dohme LLC
Phase 3
1,530
Amadora, Lisbon, Porto
2024-06-24
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Lisbon, Porto
2024-06-19
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Almada, Lisbon, Porto
2024-06-06
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Lisbon, Matosinhos Municipality, Porto
2024-06-05
Active, closed
The Efficacy of the SUN Program in Adolescents
NCT06830278Sexual Violence
Universidade do Porto
Not applicable
231
Porto
2024-06-01
Not yet open
Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography
NCT06438393Coronary Artery Disease, Coronary Atheroscleroses
Universidade do Porto
Observational
1,000
Porto
2024-06
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan
Daiichi Sankyo
Phase 3
540
Coimbra, Guimarães, Lisbon, Porto
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Guimarães, Coimbra, Almada, Braga, Guarda, Porto, Vila Nova de Gaia
2024-05-20
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor
AbbVie
Phase 3
421
Lisbon, Porto
2024-05-19
Active, closed
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942Newly Diagnosed and Recurrent Glioblastoma
DrugsGa-NeoB·Lu-NeoB
Novartis Pharmaceuticals
Phase 1
42
Porto
2024-05-15
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Lisbon, Porto
2024-05-08
By invitation
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
100
Coimbra, Lisbon, Porto
2024-04-30
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugClazakizumab
CSL Behring
Phase 2/3
3,110
Braga, Canelas-V.N.Gaia, Carregado, Faro, Lisbon, Loures, Oeiras, Porto
2024-04-27
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 3
119
Lisbon, Porto
2024-04-16
Recruiting
Management of Malignant Gastric Outlet Obstruction Between Surgery and Endoscopy
NCT06071507Gastric Outlet Obstruction, Pancreatic Cancer
IRCCS San Raffaele
Observational
250
Porto
2024-04-15
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
1,200
Lisbon, Porto
2024-04-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Lisbon, Porto
2024-04-10
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Lisbon, Matosinhos Municipality, Coimbra, Porto
2024-04-03
Active, closed
Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients
NCT06782698Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer, Early Breast Cancer, Cancer-related Fatigue
Centro Hospitalar Universitário de Santo António
Not applicable
50
Porto
2024-04-01
Recruiting
EMOTE: a Smartphone Application for Binge Eating Based on DBT Skills
NCT06683456Binge Eating
Universidade do Porto
Not applicable
68
Porto
2024-04-01
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Coimbra, Faro, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2024-03-21
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Lisbon, Porto
2024-03-14
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
120
Braga, Lisbon, Porto
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
Braga, Lisbon, Porto
2024-03-13
Active, closed
Does the Structure of the Tendon Relate to the Temporal, Kinetic and Kinematic Jump Variables? Athletes Vs. Non Athletes
NCT06732986Vertical Jump, Patellar Tendon, Achilles Tendon
Escola Superior de Tecnologia da Saúde do Porto
Observational
48
Porto
2024-03-05
Recruiting
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
NCT06165341Alpha1-Antitrypsin Deficiency
DrugFazirsiran
Takeda
Phase 3
50
Braga, Funchal, Porto
2024-03-01
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
DrugsLeuprolide·Goserelin·Exemestane·Ribociclib
Novartis Pharmaceuticals
Phase 3
1,400
Coimbra, Lisbon, Porto
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Amadora, Lisbon, Porto
2024-02-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311HIV, HIV Infections
DrugsBictegravir·Emtricitabine·Dolutegravir·Lamivudine
ViiV Healthcare
Phase 3
307
Aveiro, Porto
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Braga, Lisbon, Porto
2024-02-20
Active, closed
The Research Aims to Study the Effectiveness of a Physical Exercise Program on Indicators of Quality of Life and Functionality: It Will be Applied at Home to People Undergoing Cardiac Surgery, in Phase II of Cardiac Rehabilitation
NCT07153874Cardiac Surgery, Rehabilitation Program, Quality of Life, Functional Status
Universidade Católica Portuguesa
Not applicable
76
Porto
2024-02-19
Active, closed
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096Delayed Graft Function
DrugEmpasiprubart
argenx
Phase 2
103
Carnaxide, Lisbon, Porto
2024-02-17
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Lisbon, Porto
2024-02-09
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine
Genmab
Phase 3
1,095
Lisbon, Vila Nova de Gaia, Porto
2024-02-05
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
112
Lisbon, Porto
2024-01-19
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib
Merck Sharp & Dohme LLC
Phase 3
340
Braga, Lisbon, Porto
2023-12-31
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Braga, Lisbon, Porto
2023-12-30
Recruiting
Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment
NCT06247085Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
70
Coimbra, Lisbon, Porto
2023-12-28
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Coimbra, Lisbon, Porto
2023-12-21
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Coimbra, Leiria, Lisbon, Porto
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga
Merck Sharp & Dohme LLC
Phase 3
1,314
Alcabideche, Vila Nova de Gaia, Braga, Lisbon, Porto
2023-12-18
Not yet open
Hydrophobic Tubes for the Treament of Lower and Upper Limb Lymphedema
NCT05970068Lymphedema of Leg
Universidade do Porto
Not applicable
20
Porto
2023-12-15
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugNexiguran ziclumeran
Intellia Therapeutics
Phase 3
1,200
Lisbon, Porto
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Lisbon, Vila Nova de Gaia, Porto
2023-12-13
Active, closed
Incomplete Cervical SCI Without Instability
NCT05653206Cervical Spinal Cord Injury
AO Foundation, AO Spine
Observational
50
Porto
2023-12-11
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2023-12-11
Recruiting
Validation of the C-mo System - Cough Monitoring
NCT05989698Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux
Cough Monitoring Medical Solutions
Not applicable
300
Alfena, Amadora, Aveiro, Coimbra, Lisbon, Porto
2023-12-11
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Lisbon, Porto
2023-12-06
Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
NCT06408441Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Observational
100
Porto
2023-12-01
Recruiting
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
NCT05809986Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Observational
174
Amadora, Guimarães, Leiria, Lisbon, Matosinhos Municipality, Ponte de Lima, Porto, Setúbal
2023-11-27
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Coimbra, Lisbon, Porto, Senhora da Hora
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsSotorasib·Pembrolizumab
Amgen
Phase 3
750
Lisbon, Matosinhos Municipality, Porto
2023-11-16
Active, closed
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420Neoplasms, Head and Neck
DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab
GlaxoSmithKline
Phase 2
316
Almada, Lisbon, Porto
2023-11-14
Active, closed
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1
28
Porto
2023-11-13
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
DrugsOpdivo·Nivolumab
Amgen
Phase 3
633
Setúbal, Lisbon, Porto
2023-11-02
Recruiting
Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression
NCT06206369Aneurysm Abdominal, Peripheral Arterial Disease
Amsterdam UMC, location VUmc
Observational
11,000
Porto
2023-10-31
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Braga, Lisbon, Loures, Porto, Vila Nova de Gaia
2023-10-25
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,295
Alcabideche, Lisboa, Amadora, Lisboa, Braga, Lisbon, Loures, Porto, Vila Real
2023-10-24
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Lisbon, Porto
2023-10-13
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Almada, Lisbon, Porto
2023-10-11
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Amadora, Braga, Lisbon, Porto, Vila Nova de Gaia, Vila Real
2023-10-05
Recruiting
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367GIST
DrugRipretinib
Deciphera Pharmaceuticals, LLC
Phase 1/2
94
Porto
2023-09-28
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
DrugsLurbinectedin·Doxorubicin
PharmaMar
Phase 3
469
Lisbon, Coimbra, Porto
2023-09-21
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Faro, Lisbon, Loures, Porto, Vila Nova de Gaia
2023-09-14
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
DrugEfgartigimod PH20
argenx
Phase 3
240
Porto
2023-09-12
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
DrugSeladelpar
Gilead Sciences
Phase 3
402
Braga, Creixomil, Porto
2023-09-07
Active, closed
Exercise As Intervention in Chronic Lymphocytic Leukemia
NCT06396611Chronic Lymphocytic Leukemia
Universidade do Porto
Not applicable
11
Porto
2023-09-01
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
Lisbon, Porto
2023-08-21
Active, closed
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
NCT05797740Multiple Sclerosis
DrugsMavenclad·Cladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Observational
366
Coimbra, Lisbon, Porto
2023-08-03
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Guilhufe, Almada, Ponte de Lima, Porto
2023-07-25
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,089
Lisbon, Porto
2023-07-19
Active, closed
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
210
Lisbon, Porto
2023-07-07
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Braga, Coimbra, Porto
2023-06-22
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Lisbon, Porto
2023-06-22
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Lisbon, Porto
2023-06-21
Recruiting
Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
NCT05234723Cytomegalovirus Infections
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
100
Porto
2023-06-19
Recruiting
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320Episodic Migraine
DrugEptinezumab
H. Lundbeck A/S
Phase 3
315
Braga, Coimbra, Lisbon, Porto
2023-06-08
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Lisbon, Porto
2023-06-07
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
DrugVericiguat
Merck Sharp & Dohme LLC
Phase 2/3
342
Lisbon, Porto
2023-05-31
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Lisbon, Matosinhos Municipality, Porto
2023-05-31
Recruiting
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
NCT05562466Asthma
DrugBudesonide
Novartis Pharmaceuticals
Phase 3
200
Lisbon, Porto
2023-05-11
Recruiting
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100Focal Onset Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
360
Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira, Vila Real
2023-05-09
Recruiting
The Ailliance Post-Market Clinical Study
NCT05856370Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma
Medtronic Spinal and Biologics
Not applicable
1,000
Porto
2023-05-01
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira
2023-04-25
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Coimbra, Lisbon, Porto
2023-04-17
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Amadora, Braga, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2023-03-31
Active, closed
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359Parkinson's Disease
Bial R&D Investments, S.A.
Phase 2
237
Coimbra, Guimarães, Porto, Torres Vedras
2023-03-31
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Almada, Braga, Lisbon, Porto, Vila Nova de Gaia
2023-03-29
Recruiting
Assessment of the Role of Incisura Biopsy in the Staging of Chronic Gastritis
NCT05744596Chronic; Gastritis, Atrophic
Clinical Hospital Colentina
Observational
400
Porto
2023-03-23
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Almada, Carnaxide, Coimbra, Lisbon, Matosinhos Municipality, Porto, Santa Maria da Feira, Setúbal
2023-03-09
Recruiting
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971Alpha1-Antitrypsin Deficiency
DrugFazirsiran
Takeda
Phase 3
160
Braga, Funchal, Porto
2023-03-06
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Braga, Coimbra, Covilha, Guimarães, Lisbon, Porto, Pragal, Santa Maria da Feira
2023-02-15
Recruiting
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Primary Generalized Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
160
Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto, Santa Maria da Feira
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Coimbra, Lisbon, Porto
2023-02-13
Active, closed
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899High-risk Large B-cell Lymphoma (LBCL)
DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin
Kite, A Gilead Company
Phase 3
300
Lisbon, Porto
2023-02-10
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Braga, Lisbon, Porto
2023-02-08
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin
Daiichi Sankyo
Phase 3
1,170
Lisbon, Porto
2023-01-11
Recruiting
NEgative prEssure Wound Therapy in Renal Transplant
NCT07065734Transplant Complication, Renal Transplant, Wound Complication
Centro Hospitalar De São João, E.P.E.
Phase 4
150
Porto
2023-01-01
Recruiting
European Myeloma Network (EMN) Sample Project
NCT06237803Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma
European Myeloma Network B.V.
Observational
6,000
Coimbra, Lisbon, Porto
2022-12-21
Active, closed
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351Severe Hypertriglyceridemia
DrugOlezarsen
Ionis Pharmaceuticals, Inc.
Phase 3
885
Aveiro, Lisbon, Porto, Santa Maria da Feira
2022-12-13
Active, closed
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
DrugOpnurasib
Novartis Pharmaceuticals
Phase 2
95
Porto
2022-12-06
By invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Guimarães, Lisbon, Porto
2022-11-30
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Almada, Porto
2022-11-21
Recruiting
Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
NCT06708520Renal Impairment
DrugRupatadine
Noucor Health S.A.
Phase 1
48
Gaia, Matosinhos Municipality, Porto
2022-11-21
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
822
Lisbon, Porto
2022-11-08
Recruiting
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283Chronic Kidney Disease, Proteinuria, Children
DrugFinerenone
Bayer
Phase 3
100
Braga, Coimbra, Porto
2022-11-08
Active, closed
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
NCT05473299End-stage Renal Disease
Xeltis
Not applicable
120
Lisbon, Porto, Sacavém
2022-11-04
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Braga, Lisbon, Porto
2022-10-25
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
DrugsTucatinib·Erbitux·Herceptin·Avastin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Almada, Guarda, Lisbon, Porto
2022-10-24
Active, closed
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
NCT05345171OTC Deficiency
DrugPrednisolone
Ultragenyx Pharmaceutical Inc
Phase 3
37
Porto
2022-10-18
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Loures, Braga, Coimbra, Lisbon, Porto
2022-10-14
Active, closed
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378Lung Cancer, Non-Small Cell
DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 2
351
Gaia, Guimarães, Lisbon, Porto
2022-10-14
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891Cancer
EMD Serono Research & Development Institute, Inc.
Observational
700
Loures, Lisbon, Porto, Porto Covo
2022-10-04
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Braga, Lisbon, Porto
2022-09-27
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Almada, Braga, Porto
2022-09-23
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib
Celgene
Phase 3
810
Braga, Lisbon, Porto
2022-09-20
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 2/3
450
Coimbra, Lisbon, Porto, Viana do Castelo
2022-09-13
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Braga, Lisbon, Porto, Vila Real
2022-09-08
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Lisbon, Porto
2022-08-30
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2/3
1,856
Lisbon, Porto
2022-08-22
Active, closed
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
NCT05494606Ulcerative Colitis
AbbVie
Observational
785
Funchal, Almada, Faro, Lisbon, Loures, Porto, Viseu
2022-08-15
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Carnaxide, Coimbra, Lisbon, Porto, Vila Nova de Gaia
2022-08-10
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 3
412
Lisbon, Porto, Vila Nova de Gaia
2022-08-10
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Lisbon, Portimão, Porto, Santa Maria da Feira
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Lisbon, Braga, Porto
2022-07-21
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab
Hoffmann-La Roche
Phase 3
922
Coimbra, Lisbon, Loures, Porto
2022-07-18
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
DrugsDepemokimab·Mepolizumab
GlaxoSmithKline
Phase 3
163
Lisbon, Porto
2022-07-14
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Lisbon, Porto
2022-07-08
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
DrugsGoserelin·Tamoxifen·Anastrozole·Ribociclib
Novartis Pharmaceuticals
Phase 4
134
Lisbon, Loures, Porto
2022-07-07
Recruiting
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
NCT05203172Solid Tumors
Pfizer
Phase 4
210
Lisbon, Porto
2022-07-05
Active, closed
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613Erosive Esophagitis
DrugNexium
AstraZeneca
Phase 3
53
Coimbra, Lisbon, Porto, Viana do Castelo
2022-07-01
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Coimbra, Lisbon, Porto
2022-06-23
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
DrugsOpnurasib·Docetaxel
Novartis Pharmaceuticals
Phase 3
95
Matosinhos Municipality, Porto
2022-06-15
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Braga, Carnaxide, Lisbon, Loures, Porto, Setúbal, Vila Franca de Xira, Vila Nova de Gaia
2022-05-30
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Lisbon, Porto
2022-05-23
Recruiting
Effects of Exergaming to Reduce Sedentary Time in Inactive Patients With Heart Failure
NCT05641662Cardiovascular Diseases
Linkoeping University
Not applicable
750
Porto
2022-05-16
Active, closed
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728Glioblastoma
Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera
Novartis Pharmaceuticals
Phase 1
63
Porto
2022-05-10
Active, closed
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
NCT05296746Breast Cancer Stage II
DrugRibociclib
SOLTI Breast Cancer Research Group
Phase 2
1,100
Lisbon, Porto
2022-05-03
Active, closed
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
NCT05270044Melanoma
Pierre Fabre Medicament
Phase 3
815
Lisbon, Porto
2022-05-02
Active, closed
Alternative Healthcare Delivery Strategies to Prevent Weight Regain After Bariatric Surgery
NCT05946187Obesity Adult Onset, Eating Behavior
University of Minho
Not applicable
144
Porto
2022-05-01
Recruiting
Autism Spectrum Disorder: BAEPs Findings and Behavioral Responses to Sounds
NCT05520632Autism Spectrum Disorder
Instituto de Ciências Biomédicas Abel Salazar
Observational
120
Porto
2022-05-01
Recruiting
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617Seizures, Lennox Gastaut Syndrome
SK Life Science, Inc.
Phase 3
252
Lisbon, Porto, Almada
2022-04-28
Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550Non-small Cell Lung Cancer
DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab
AstraZeneca
Phase 2
630
Lisbon, Porto
2022-04-14
Recruiting
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
NCT05356741Locally Advanced or Metastatic HER2-Expressing Cancers
DrugsKeytruda·Pembrolizumab
Vir Biotechnology, Inc.
Phase 1/2
645
Porto
2022-04-13
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Braga, Carnaxide, Porto
2022-04-05
Active, closed
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790Polycythemia Vera
DrugRusfertide
Protagonist Therapeutics, Inc.
Phase 3
293
Almada, Braga, Lisbon, Porto
2022-04-01
Active, closed
Tissue Level vs Bone Level Implants for Plural Restorations : a Multicentre Randomised Controlled Trial
NCT05223387Dental Implants, Edentulous
Anthogyr
Not applicable
40
Porto
2022-03-30
Active, closed
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035Chronic Kidney Disease, Proteinuria
DrugFinerenone
Bayer
Phase 3
219
Coimbra, Porto
2022-03-28
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
DrugsTelisotuzumab vedotin·Docetaxel
AbbVie
Phase 3
768
Lisbon, Porto
2022-03-25
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide
Merck Sharp & Dohme LLC
Phase 3
460
Lisbon, Porto
2022-03-24
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553Active Juvenile Psoriatic Arthritis
DrugApremilast
Amgen
Phase 3
60
Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia
2022-03-17
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Braga, Carnaxide, Lisbon, Porto
2022-03-15
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab
BeOne Medicines
Phase 3
799
Braga, Porto, VILA NOVA de GAIA Porto
2022-03-10
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Lisbon, Porto
2022-03-08
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
DrugsDato-DXd·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
740
Lisbon, Porto
2022-03-04
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Lisbon, Porto
2022-02-21
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
Lisbon, Loures, Porto
2022-02-07
Active, closed
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
DrugRozanolixizumab
UCB Biopharma SRL
Phase 3
113
Coimbra, Porto
2022-02-02
Active, closed
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
NCT05071300Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
DrugEplontersen
Ionis Pharmaceuticals, Inc.
Phase 3
151
Lisbon, Porto
2022-01-04
Active, closed
Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System
NCT05354440Prostate Cancer
BioProtect
Observational
80
Porto
2022-01-01
Active, closed
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735Breast Cancer
DrugsAlpelisib·Fulvestrant
Novartis Pharmaceuticals
Phase 3
210
Coimbra, Lisbon, Porto
2021-12-17
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Erbitux·Cetuximab
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Braga, Lisbon, Porto, Vila Nova de Gaia
2021-12-10
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil
Jazz Pharmaceuticals
Phase 3
920
Almada, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto
2021-12-02
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Lisbon, Porto
2021-12-01
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172Migraine
DrugEptinezumab
H. Lundbeck A/S
Phase 3
600
Almada, Porto Covo, Braga, Coimbra, Porto
2021-12-01
Recruiting
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3
534
Lisbon, Porto
2021-11-30
Recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium
Observational
300
Chaves, Coimbra, Porto
2021-11-18
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
DrugsSacituzumab Govitecan·Docetaxel
Gilead Sciences
Phase 3
603
Coimbra, Lisbon, Matosinhos Municipality, Porto
2021-11-17
Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925Primary Immune Thrombocytopenia
DrugEfgartigimod PH20
argenx
Phase 3
173
Lisbon, Porto, Vila Nova de Gaia
2021-11-17
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
776
Lisbon, Loures, Porto
2021-11-17
Active, closed
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
DrugBlinatumomab
Amgen
Phase 3
303
Coimbra, Lisbon, Porto
2021-11-02
Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Bayer
Phase 1/2
400
Lisbon, Porto
2021-10-25
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Porto, Vila Nova de Gaia
2021-10-06
Active, closed
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
NCT04884815Wilson Disease
Ultragenyx Pharmaceutical Inc
Phase 1/2
82
Lisbon, Porto
2021-09-27
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Truxima·Pirtobrutinib
Loxo Oncology, Inc.
Phase 3
282
Braga, Lisbon, Porto
2021-09-23
Recruiting
International Rare And Severe Psoriasis Expert Network
NCT04359394Pustular Psoriasis (PP)
University Hospital, Basel, Switzerland
Observational
180
Porto
2021-09-22
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugsTremfya·Guselkumab
Janssen Research & Development, LLC
Phase 4
411
Braga, Guarda, Lisbon, Ponte de Lima, Porto
2021-08-30
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
DrugsKeytruda·Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2
115
Lisbon, Porto
2021-08-27
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Lisbon, Guimarães, Loures, Porto, Vila Nova de Gaia, Vila Real
2021-08-27
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine
Janssen Research & Development, LLC
Phase 3
743
Lisbon, Porto
2021-08-19
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Braga, Guimarães, Lisbon, Porto, Senhora da Hora, Vila Real
2021-08-19
Recruiting
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH
Phase 2
213
Porto
2021-08-18
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
DrugBelzutifan
Merck Sharp & Dohme LLC
Phase 2
355
Lisbon, Porto
2021-08-12
Active, closed
Pulmonary Embolism International THrOmbolysis Study-3
NCT04430569Pulmonary Embolism
DrugAlteplase
Assistance Publique - Hôpitaux de Paris
Phase 3
800
Almada, Lisbon, Matosinhos Municipality, Porto, Setúbal
2021-08-04
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
DrugZongertinib
Boehringer Ingelheim
Phase 1
554
Porto
2021-07-02
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib
AstraZeneca
Phase 3
315
Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2021-06-30
Recruiting
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675Chronic Migraine in Children
DrugEptinezumab
H. Lundbeck A/S
Phase 3
285
Almada, Coimbra, Porto
2021-06-30
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsAdagrasib·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Braga, Lisbon, Porto
2021-06-24
Active, closed
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761Breast Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 3
506
Lisbon, Porto
2021-06-22
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol
Merck Sharp & Dohme LLC
Phase 3
342
Lisbon, Matosinhos Municipality, Porto
2021-06-18
By invitation
ManAgement of pRiapiSm and Its Impact on Outcomes
NCT04932902Priapism
Policlinic Hospital "G. Rodolico"
Observational
200
Porto
2021-06-01
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Braga, Lisbon, Porto
2021-05-26
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel
Daiichi Sankyo
Phase 3
490
Creixomil E Mariz, Porto, Vila Real
2021-05-21
Active, closed
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
NCT04544293Autoimmune Pulmonary Alveolar Proteinosis
DrugMolgramostim
Savara Inc.
Phase 3
164
Lisbon, Porto
2021-05-19
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
DrugAlectinib
Hoffmann-La Roche
Observational
800
Porto, Vila Nova de Gaia
2021-05-10
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab
Hoffmann-La Roche
Phase 3
1,188
Lisbon, Loures, Porto
2021-05-04
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
808
Coimbra, Lisbon, Porto
2021-04-21
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,205
Senhora Da Hora, Matosinhos, Almada, Aveiro, Braga, Guarda, Guimarães, Lisbon, Porto
2021-04-01
Active, closed
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
NCT04944979Primary Immunodeficiency Disease
DrugKedrion IVIG
Kedrion S.p.A.
Phase 3
30
Lisbon, Porto
2021-03-31
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010Relapsing Multiple Sclerosis
DrugsFenebrutinib·Teriflunomide
Hoffmann-La Roche
Phase 3
746
Braga, Coimbra, Lisbon, Porto, Santa Maria da Feira
2021-03-17
Active, closed
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
NCT04775082Obesity
DrugLiraglutide
Novo Nordisk A/S
Phase 3
78
Lisbon, Porto
2021-03-04
Recruiting
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
NCT04710576Chronic Graft-versus-host-disease
DrugAxatilimab
Syndax Pharmaceuticals
Phase 2
296
Lisbon, Porto
2021-03-04
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
DrugsAdagrasib·Taxotere·Docetaxel
Mirati Therapeutics Inc.
Phase 3
453
Almada, Braga, Coimbra, Guimarães, Lisbon, Loures, Porto, Santa Maria da Feira
2021-02-23
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Braga, Lisbon, Porto, Vila Nova de Gaia
2021-02-23
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Palbociclib
AstraZeneca
Phase 3
1,371
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2021-01-28
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib
Hoffmann-La Roche
Phase 2
920
Porto
2021-01-18
Recruiting
SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up
NCT04613570Atrophic Gastritis, Intestinal Metaplasia, Gastric Dysplasia, Gastric Cancer
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Not applicable
912
Porto
2021-01-02
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 2
220
Almada, Aveiro, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia, Vila Real
2020-12-18
Active, closed
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Biosciences
Phase 3
182
Porto
2020-12-16
Active, closed
AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT
NCT04225520Left Ventricular Dyssynchrony, Heart Failure, Cardiomyopathy, Dilated, Cardiac Remodeling, Ventricular
Universitaire Ziekenhuizen KU Leuven
Not applicable
500
Porto
2020-12-10
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
DrugsOlaparib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
672
Lisbon, Porto
2020-12-08
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin
Janssen Research & Development, LLC
Phase 3
518
Almada, Coimbra, Lisbon, Porto
2020-12-07
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Guimarães, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia
2020-12-04
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
769
Braga, Lisbon, Porto
2020-12-03
Active, closed
Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy
NCT04463641Heart Failure, Cardiac Resynchronization Therapy
MicroPort CRM
Not applicable
92
Lisbon, Porto
2020-12-03
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Coimbra, Guimarães, Lisbon, Porto, Vila Nova de Gaia
2020-12-02
Recruiting
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
NCT04561518Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Alnylam Pharmaceuticals
Observational
1,500
Lisbon, Porto
2020-11-23
Active, closed
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059Prostatic Neoplasms
DrugsLhrha·Apalutamide
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Lisbon, Porto, Santa Maria da Feira
2020-11-12
Recruiting
LANDMARK Trial: a Randomised Controlled Trial of Myval THV
NCT04275726Aortic Valve Stenosis
Meril Life Sciences Pvt. Ltd.
Not applicable
988
Carnaxide, Lisbon, Porto
2020-11-04
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449Multiple Sclerosis, Primary Progressive
DrugsFenebrutinib·Ocrelizumab
Hoffmann-La Roche
Phase 3
985
Braga, Lisbon, Porto
2020-10-26
By invitation
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
NCT04574076Haemophilia A
DrugTuroctocog alfa pegol
Novo Nordisk A/S
Observational
60
Lisbon, Porto
2020-10-23
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
DrugDarolutamide
Bayer
Phase 3
402
Almada, Lisbon, Porto
2020-10-20
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma
DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate
Exelixis
Phase 3
575
Braga, Guimarães, Lisbon, Loures, Porto, Vila Real
2020-10-19
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
Lisbon, Porto, Vila Nova de Gaia
2020-10-13
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
DrugsGiredestrant·Palbociclib·Letrozole
Hoffmann-La Roche
Phase 3
992
Coimbra, Lisbon, Porto
2020-10-09
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Braga, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2020-10-08
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
DrugsCrovalimab·Eculizumab
Hoffmann-La Roche
Phase 3
210
Aveiro, Lisbon, Porto
2020-10-08
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
DrugsMonalizumab·Erbitux·Cetuximab
AstraZeneca
Phase 3
370
Coimbra, Porto, Vila Nova de Gaia
2020-10-02
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584Paroxysmal Nocturnal Hemoglobinuria
DrugsCrovalimab·Eculizumab
Hoffmann-La Roche
Phase 3
190
Aveiro, Porto
2020-09-30
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Lisbon, Porto
2020-09-30
Active, closed
An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device (bRIGHT)
NCT04483089Tricuspid Valve Regurgitation
Abbott Medical Devices
Observational
511
Porto
2020-08-27
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
185
Lisbon, Porto
2020-08-04
Active, closed
Personalized Therapy Study - HFRS (TriageHF) Post Approval Study
NCT04489225Heart Failure
Medtronic
Observational
2,200
Guimarães, Lisbon, Porto, Santarém
2020-08-01
Active, closed
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
NCT04496518Ventricular Tachycardia
Medtronic
Observational
2,200
Guimarães, Lisbon, Porto, Santarém
2020-08-01
Recruiting
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576Leukemia, Acute Lymphoblastic
DrugsInotuzumab Ozogamicin·Imatinib·Blinatumomab
Mats Heyman
Phase 3
6,430
Coimbra, Lisbon, Porto
2020-07-13
Recruiting
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542Prostate Cancer
DrugsXaluritamig·Abiraterone·Enzalutamide
Amgen
Phase 1
479
Lisbon, Porto
2020-03-04
Active, closed
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154Chemotherapy-induced Thrombocytopenia
DrugsNplate·Romiplostim
Amgen
Phase 3
145
Lisbon, Matosinhos Municipality, Porto
2020-02-26
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
DrugsInavolisib·Palbociclib·Fulvestrant
Hoffmann-La Roche
Phase 2/3
325
Lisbon, Porto
2020-01-29
Active, closed
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
NCT04175600Hypertension, Pulmonary
DrugSelexipag
Actelion
Phase 3
138
Lisbon, Porto
2020-01-16
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsMobocertinib·Pemetrexed·Cisplatin·Carboplatin
Takeda
Phase 3
354
Santa Maria da Feira, Vila Nova de Gaia, Lisbon, Porto
2020-01-10
Recruiting
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
NCT03969329Secondary Hyperparathyroidism
DrugEtelcalcetide
Amgen
Phase 3
24
Porto
2019-12-20
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Lisbon, Porto
2019-12-17
Active, closed
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT04153149Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
655
Lisbon, Coimbra, Faro, Guimarães, Porto
2019-11-26
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Porto
2019-11-13
Recruiting
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
NCT04032470Essential Tremor
Boston Scientific Corporation
Observational
500
Porto
2019-10-23
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
NCT04083781Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
134
Porto
2019-10-21
Active, closed
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877Multiple Sclerosis, Relapsing-Remitting
DrugsPlegridy·Avonex
Biogen
Phase 3
152
Lisbon, Loures, Braga, Coimbra, Porto
2019-10-18
Recruiting
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919Acute Promyelocytic Leukemia
DrugsMylotarg·All-trans retinoic acid·Arsenic Trioxide·ATRA
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2
89
Coimbra, Lisbon, Porto
2019-10-09
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
DrugGuselkumab
Janssen Research & Development, LLC
Phase 2/3
1,064
Coimbra, Porto, Santa Maria da Feira, Viseu
2019-09-26
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Almada, Coimbra, Lisbon, Porto
2019-09-23
Active, closed
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232Ulcerative Colitis
DrugEtrasimod
Pfizer
Phase 3
896
Vila Nova de Gaia, Coimbra, Guimarães, Porto
2019-09-05
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494Lymphoblastic Lymphoma, Childhood
DrugsVindesine·Thioguanine·PEG-Asparaginase·Mercaptopurine
University Hospital Muenster
Phase 3
683
Coimbra, Lisbon, Porto
2019-08-23
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
Lisbon, Porto
2019-08-20
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Braga, Lisbon, Porto
2019-08-15
Active, closed
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005Multiple Sclerosis, Primary Progressive
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,013
Loures, Almada, Braga, Porto, Torres Vedras
2019-08-12
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
DrugsRucaparib·Sunitinib·Relatlimab·Trametinib
Bristol-Myers Squibb
Phase 2
1,500
Lisbon, Porto
2019-08-09
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
DrugsCapivasertib·Paclitaxel
AstraZeneca
Phase 3
923
Lisbon, Porto
2019-06-25
Active, closed
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
NCT03609047Breast Cancer Stage II, Breast Cancer Stage III
DrugsDoxorubicin/cyclophosphamide·Palbociclib·Paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
366
Lisbon, Porto
2019-06-14
Active, closed
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
NCT03992417Dermatitis Atopic
DrugDupilumab
Sanofi
Observational
955
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2019-06-11
Active, closed
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
OHB Neonatology Ltd.
Phase 2
295
Almada, Lisbon, Porto
2019-05-09
Active, closed
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561Diabetes Mellitus, Type 2
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,500
Senhora Da Hora, Matosinhos, Almada, Aveiro, Coimbra, Guimarães, Lisbon, Porto, Setúbal
2019-05-08
Active, closed
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
NCT03869892Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Capecitabine
Institut de Recherches Internationales Servier
Phase 3
856
Almada, Coimbra, Lisbon, Loures, Porto
2019-03-21
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
DrugsNiraparib·Abiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 3
765
Coimbra, Lisbon, Porto
2019-01-25
Active, closed
9-ING-41 in Patients With Advanced Cancers
NCT03678883Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
DrugsCCNU·Lomustine·Abraxane·Adriamycin
Actuate Therapeutics Inc.
Phase 2
350
Lisbon, Porto
2019-01-04
Active, closed
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
NCT03682536Myelodysplastic Syndromes
DrugsEpoetin Alfa·Luspatercept
Celgene
Phase 3
363
Beja, Braga, Lisbon, Porto, Setúbal
2019-01-02
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab
Novartis Pharmaceuticals
Phase 3
1,882
Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto, Santa Maria da Feira
2018-12-28
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
DrugsEpirubicin·Adriamycin·Cytoxan·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,240
Lisboa, Lisbon, Porto
2018-12-27
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
DrugsKeytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,397
Braga, Coimbra, Lisbon, Porto
2018-12-24
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
Braga, Lisbon, Porto
2018-12-17
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Braga, Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira, Setúbal, Vila Real
2018-11-28
Recruiting
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157Spinal Muscular Atrophy (SMA)
DrugZolgensma
Novartis Pharmaceuticals
Observational
700
Coimbra, Lisbon, Porto
2018-09-25
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,242
Guimarães, Portimão, Santa Maria DA Feira, Almada, Coimbra, Lisbon, Porto, Viseu
2018-08-28
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
3,500
Lisbon, Porto
2018-08-21
Active, closed
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545Heart Failure
Biotronik SE & Co. KG
Observational
3,030
Carnaxide, Evora, Lisbon, Porto
2018-05-14
Active, closed
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT03530397Selected Advanced Solid Tumors
DrugsVolrustomig·Nab-paclitaxel·Pemetrexed·Paclitaxel
MedImmune LLC
Phase 1
400
Lisbon, Porto
2018-04-24
Active, closed
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc.
Observational
500
Coimbra, Lisbon, Porto
2018-04-23
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab
Janssen Research & Development, LLC
Phase 2/3
1,409
Braga, Coimbra, Guimarães, Portimão, Porto, Santa Maria da Feira
2018-04-13
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,336
Guimarães, Portimão, Lisbon, Santa Maria DA Feira, Almada, Faro, Loures, Porto
2018-04-09
Active, closed
Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801Age Related Macular Degeneration (AMD)
Frank G. Holz
Observational
718
Coimbra, Porto
2018-03-26
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
629
Lisbon, Porto
2018-03-23
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
747
Guimarães, Lisbon, Almada, Ponte de Lima, Porto
2018-03-21
Rows per page Showing 1–500 of 541
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/porto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,100 studies in total at the last sync on 03 Oct 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 541 of those studies with a site in Porto.

How many clinical trials are recruiting in Porto?

239 of the 541 studies on this page are recruiting new participants as of the 03 Oct 2026, 03:16 UTC sync. A further 34 have not yet opened recruitment, 252 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Porto), 541 studies
PhaseStudiesRecruitingShare
Phase 330011755.5%
Not applicable723413.3%
Observational683712.6%
Phase 246218.5%
Phase 2/323134.3%
Phase 11142%
Phase 41162%
Phase 1/21071.8%

Most active sponsors

Lead sponsors with the most studies (Porto)
Lead sponsorStudiesRecruiting
Universidade do Porto339
Janssen Research & Development, LLC3013
AbbVie2610
AstraZeneca269
Hoffmann-La Roche244
Merck Sharp & Dohme LLC2312
Novartis Pharmaceuticals229
Amgen146
Novo Nordisk A/S132
Daiichi Sankyo126
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.